Document is current

Article History

Received: 24 April 2025

Accepted: 19 September 2025

First Online: 13 October 2025

Declarations

:

: Salvatore Tafuto: has performed consultancy, has been a member of advisory boards, and has received fees from AAA, Novartis, Ipsen, Esteve, Deciphera, Boehringer. Secondo Lastoria has received fees for participating on Advanced Accelerator Applications (AAA) advisory boards. Lorenzo Antonuzzo has received payment or honoraria for lectures and presentation from AstraZeneca, Roche, Astellas, Novartis, MSD, BMS, Ipsen, Merck Serono, Amgen, Bayer; Support for attending meetings and/or travel grants from AstraZeneca, Novartis, Ipsen, Merck Serono, his institution received research funding from Novartis, AstraZeneca. Sara Cingarlini has received speaker’s fees from Novartis, Pierre Fabre, and Bristol Myers. Mauro Cives has performed consultation for AAA – Novartis, Advanz, Esteve, Camurus, Harbour Biomed, Harpoon Therapeutics, and has received speaker’s fees from AAA – Novartis and Ipsen. Diego Ferone has been a consultant for AAA – Novartis, Camurus, Recordati RD, and received speaker’s fees or research grants from Camurus, Recordati RD. Angelina Filice has received speaker’s fees from Novartis and has performed consultations for Novartis. Dario. Giuffrida attended meetings and/or received travel grants from Novartis, Ipsen, Merck Serono, his institution received research funding novartis. Marco Maccauro has received speaker’s fees from AAA – Novartis and Boston Scientific. Nicola Fazio declares financial Interests related to Astellas, Advisory Board, Personal; Astellas, Invited Speaker, Personal; Ipsen, Advisory Board, Personal; ITM, Advisory Board, Personal; Merck, Advisory Board, Personal; Novartis, Other, Personal, Steering committee; Novartis, Invited Speaker, Personal; Novartis, Advisory Board, Personal; Astellas, Local PI, Institutional, Financial interest; Boehringer, Local PI, Institutional, Financial interest; Fibrogen, Local PI, Institutional, Financial interest; Ipsen, Local PI, Institutional, Financial interest; Ipsen, Research Grant, Institutional, Financial interest; ITM, Local PI, Institutional, Financial interest; Merck, Research Grant, Institutional, Financial interest: MSD, Local PI, Institutional, Financial interest; Novartis, Research Grant, Institutional, Financial interest; Revolution medicine, Local PI, Institutional, Financial interest and non-financial interests related to AIOM, Other, Internal reviewer of NET guidelines; ENETS, Other, President elect; ESMO, Other, Member of the NET Faculty; ITANET, Other, Member of the scientific board; SPARC Europe, Other, Steering committee. Francesco Panzuto, Davide Campana, Dario Giuffrida, Stefano Partelli declare no conflict of interest.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.